Malaysian Genomics to Offer World's First DNA-Driven Fertility Test

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Under the strategic collaboration, Divine Genes' genetic test for reproductive health will be added to Malaysian Genomics' genetic test portfolio, which will market and distribute these tests in Malaysia and overseas.

Metadata
Provider: 
ACN NewswireACN Newswire
Retrieved on: 
Wednesday, February 22, 2023
Information
Tags: 
Fertility, Reproductive medicine, Genomics, Patient, Gene, Antibiotics
Geotags: 
MALAYSIA, MIDDLE EAST
⚠ partially generated by AI ↴
Organisation: 
MALAYSIAN GENOMICS RESOURCE CENTRE, MALAYSIAN GENOMICS RESOURCE CENTRE BHD
Stock Symbol: 
KualaLumpur:0155
KualaLumpur:MGRC
Summary
Key Points: 
  • Under the strategic collaboration, Divine Genes' genetic test for reproductive health will be added to Malaysian Genomics' genetic test portfolio, which will market and distribute these tests in Malaysia and overseas.
  • Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, "Decreasing fertility and birth rates are common across the world, and demand for reproductive medicine is growing in many countries.
  • This new, pioneering DNA-driven fertility test can help reproductive health specialists and their patients make important decisions in support of improving the outcome of fertility treatments.
  • This test will form a critical part of Malaysian Genomics' genetic screening portfolio of over 550 tests available across Southeast Asia and the Middle East where we have a presence."




Group in strategic collaboration with Divine Genes to offer genetic tests related to reproductive health in Malaysia and overseas

PETALING JAYA, Malaysia, Feb 22, 2023 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a strategic collaboration agreement with Divine Genes Sdn Bhd to collaborate on business opportunities in relation to the improvement and international distribution of genetic tests for reproductive health.
Sasha Nordin, Chief Executive Officer of Malaysian Genomics Resource Centre Berhad



Divine Genes is an investment holding company with businesses in pharmaceutical product distribution, financial consultancy services as well as general merchandise and trading.

Under the strategic collaboration, Divine Genes' genetic test for reproductive health will be added to Malaysian Genomics' genetic test portfolio, which will market and distribute these tests in Malaysia and overseas. Both parties will also cooperate in improving the product.

En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, "Decreasing fertility and birth rates are common across the world, and demand for reproductive medicine is growing in many countries. This new, pioneering DNA-driven fertility test can help reproductive health specialists and their patients make important decisions in support of improving the outcome of fertility treatments. This test will form a critical part of Malaysian Genomics' genetic screening portfolio of over 550 tests available across Southeast Asia and the Middle East where we have a presence."

Dr. Pawel Suwinski, Director of Divine Genes said, "This is a good opportunity for us to work with an organisation with the market reach, track record and platform to distribute our test. This collaboration is a good platform for both parties to leverage on each other's strengths in improving the product and expanding the market for the test."

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Source: Malaysian Genomics Resource Centre Bhd

Copyright 2023 ACN Newswire . All rights reserved.